Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist that reduces appetite and improves glucose control, while creatine is a widely used supplement that enhances muscle performance and mass
J Exp Med (2007) 204(12):280312.10.1084/jem.20071397 84 DuanLChenJZhangHYangHZhuPXiongAet alInterleukin-33 ameliorates experimental colitis through promoting Th2/Foxp3(+) regulatory T-cell responses in mice
Stay hydrated and monitor bowel patterns closely
This is especially critical for GLP-1 agonist users, where reduced appetite makes it easy to undereat protein dramatically
For many patients, this gentler approach can reduce common side effects like gastrointestinal discomfort while still improving metabolic health
References Bozzetto, L., Alderisio, A., Giorgini, M., et al